MRK240823C121000
- 0.01
- -0.01-50.00%
Merck & Co Newsroom
With 78% Ownership, Merck & Co., Inc. (NYSE:MRK) Boasts of Strong Institutional Backing
Merck, Bristol Myers Cancer Drugs Included in September FDA Advisory Panel Meeting
Here Is What to Know Beyond Why Merck & Co., Inc. (MRK) Is a Trending Stock
Express News | Merck & Co Inc: FDA's Odac Meeting to Discuss Pd-L1 Expression Thresholds Will Be Held on Sept. 26, 2024
Merck's Ebola Vaccine Showed 84% Effectiveness During Large Outbreak In Africa
Health Canada Approves Keytruda Drug to Treat Advanced Bladder Cancer
Express News | Health Canada Approves Keytruda® for the Treatment of Adult Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer (Muc) With No Prior Systemic Therapy for Muc, in Combination With Enfortumab Vedotin
Jim Cramer Says He Has 'Tremendous Faith' Merck (MRK) CEO
UBS Group: Maintains buy rating for Collenbutte Biotech-B, target price increased to HKD 215.5.
UBS Group released a research report stating that it maintains a "buy" rating on CStone Pharmaceuticals - B (06990), and at the same time raises revenue forecast for the company from 2024 to 2026 by 17%, 20%, and 21% respectively, and the target price is increased from HKD 180.9 to HKD 215.5. The company's revenue in the first half of the year increased by 32% year-on-year to RMB 1.38 billion, in line with market expectations, and recorded a first-half net profit of RMB 0.31 billion. The report pointed out that it is worth noting that the main item of the company's revenue in this period is a payment of RMB 0.641 billion from Merck and a contracted liability of RMB 0.508 billion. The bank is bullish on CStone Pharmaceuticals.
Big Pharma Stocks: Who's Leading the Race and Who's Slipping?
FTC Says FDA Biosimilar Guidance Would Increase Competition, Lead to Lower Prices
Kelong Botai Biotechnology releases its mid-term performance. Shareholders' attributable net profit is RMB 310 million, and the year-on-year loss is turned into a profit.
Kolon Life Science-B (06990) released its interim results for the six months ending June 30, 2024, with revenue of 1.383 billion yuan (RMB, same below), a year-on-year increase of 32.2%; gross profit of 1.077 billion yuan, a year-on-year increase of 59.4%; shareholder's profit of 0.31 billion yuan, compared to a loss of 31.13 million yuan in the same period last year, turning losses into gains year-on-year; and earnings per share of 1.41 yuan. The announcement stated that the revenue growth is mainly due to the group's strengthened cooperation with Merck, and the receipt of milestone payments totaling $90 million in the first half of 2024.
Merck & Co's Options: A Look at What the Big Money Is Thinking
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Merck & Co., Inc. (MRK): The Best Defensive Stock Now According to Hedge Funds?
Trending Stocks This Week as U.S. Equities Notch Their Best Week of 2024
Merck & Co., Inc. (MRK): Hedge Funds Are Bullish on This Diabetes Stock Now
Merck's (NYSE:MRK) Strong Earnings Are Of Good Quality
HK Stocks Changes | Kexinbotai Biotechnology-B (06990) rose nearly 8% in the afternoon. The company has reached multiple collaborations with Merck, and multiple potential catalysts are expected to be gradually realized.
Koronbotai Biotechnology-B(06990) rose nearly 8% in the afternoon. As of press time, it rose 6.69%, reported 164.2 Hong Kong dollars, and the turnover was 71.7501 million Hong Kong dollars.
Medicare Negotiates Lower Prices for 10 High-cost Drugs